GlassScriptPhysician profile
Srinivas C Kota
NPI 1659481562
$3,641.83
in general payments reported to CMS, 2019-2025
23 companies · $13.80 in 2025
The $13.80 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $830 · 2021: $390 · 2022: $338 · 2023: $581 · 2024: $616 · 2025: $13.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $640.06 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $582.92 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $427.80 | 2024-2025 | Zenpep |
| Abbvie INC. | $347.54 | 2022-2024 | |
| Lilly USA, LLC | $297.02 | 2019-2022 | |
| Novo Nordisk INC | $214.93 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $213.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $142.93 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.32 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $115.96 | 2019-2021 | |
| Amarin Pharma, INC. | $97.37 | 2019-2020 | |
| Glaxosmithkline, LLC. | $88.48 | 2019-2021 | |
| Eisai INC. | $51.13 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $47.89 | 2019 | |
| Dexcom, INC. | $42.14 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $39.49 | 2019 | |
| Abbott Laboratories | $37.76 | 2019-2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $31.01 | 2019 | |
| Hikma Pharmaceuticals USA | $30.39 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $27.72 | 2023 | Livalo |
| Teva Pharmaceuticals USA, INC. | $17.42 | 2020 | |
| Eyevance Pharmaceuticals LLC | $14.96 | 2021 | |
| Avion Pharmaceuticals | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Kota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.